Meghan C. Thompson, MD

Fellow in Hematology & Medical Oncology
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center

N/A

Poster(s):

• 2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes